Oppenheimer Holdings, Inc. restated their hold rating on shares of Axovant Sciences Ltd. (NASDAQ:AXON) in a research note issued to investors on Sunday. Oppenheimer Holdings also issued estimates for Axovant Sciences’ Q3 2018 earnings at ($0.54) EPS, Q4 2018 earnings at ($0.51) EPS, FY2018 earnings at ($2.34) EPS, FY2019 earnings at ($2.00) EPS, FY2020 earnings at ($1.54) EPS and FY2022 earnings at ($0.79) EPS.
Several other analysts have also commented on the company. Piper Jaffray Companies reaffirmed a hold rating on shares of Axovant Sciences in a report on Friday, November 10th. Zacks Investment Research lowered Axovant Sciences from a buy rating to a hold rating in a report on Thursday, November 9th. Chardan Capital reaffirmed a sell rating and set a $3.00 target price on shares of Axovant Sciences in a report on Friday, November 3rd. Robert W. Baird reaffirmed a hold rating and set a $6.00 target price on shares of Axovant Sciences in a report on Wednesday, November 1st. Finally, HC Wainwright reissued a buy rating on shares of Axovant Sciences in a report on Thursday, October 19th. Four analysts have rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company’s stock. Axovant Sciences presently has an average rating of Hold and a consensus target price of $14.13.
Shares of Axovant Sciences (NASDAQ AXON) opened at $5.03 on Friday. Axovant Sciences has a 1-year low of $4.60 and a 1-year high of $27.98. The company has a quick ratio of 5.94, a current ratio of 5.94 and a debt-to-equity ratio of 0.34.
Axovant Sciences (NASDAQ:AXON) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.12). sell-side analysts anticipate that Axovant Sciences will post -2.16 earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AXON. FMR LLC lifted its position in shares of Axovant Sciences by 968.5% in the second quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock valued at $167,794,000 after acquiring an additional 6,558,462 shares in the last quarter. Janus Henderson Group PLC purchased a new position in shares of Axovant Sciences in the second quarter valued at approximately $47,854,000. OxFORD Asset Management LLP lifted its position in shares of Axovant Sciences by 842.1% in the third quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock valued at $5,838,000 after acquiring an additional 777,505 shares in the last quarter. Capital Research Global Investors lifted its position in shares of Axovant Sciences by 21.8% in the second quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock valued at $80,094,000 after acquiring an additional 619,226 shares in the last quarter. Finally, Eagle Asset Management Inc. purchased a new position in shares of Axovant Sciences in the third quarter valued at approximately $4,471,000.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with our FREE daily email newsletter.